Abstract
Introduction: Total hip replacement (THR) is one of the most successful surgical procedures globally for managing end-stage hip osteoarthritis. Latitud™ hip replacement system is at the forefront of restoring mobility and improving patient outcomes. This study aimed to evaluate the safety and effectiveness of the Latitud™ hip replacement in total hip arthroplasty. Methods: In this retrospective, single-centre, post-market, observational study, 150 patients who underwent total hip replacement and were treated in our hospital from 2018–2020 were included. The primary outcome was the THR-related intra and postoperative complications and revision rate at 1-year follow-up. Secondary outcomes were other patient-reported outcomes, radiographic analysis, Harris hip score, adverse events, implant dislocation, and survivorship rate. Results: The mean age of the patients was 53.90 ± 11.44 years. The surgical procedures were successful without any major complications. There was a significant (p < 0.001) improvement in the Harris hip score. No death was observed throughout the study. There was 1 (0.67%) intra-operative fracture, with the patient having a closed comminuted fracture of the upper and middle third of the left femur and anemia. Seven patients (4.67%) patients required postoperative blood transfusions. During the follow-up period, there was no revision surgery or implant dislocation. Conclusion: This observational study suggests that the Latitud™ hip replacement system was favorable safety and effective in a real-world setting in Kazakhstan. The study showed promising results in pain alleviation, functional improvement, and implant survivorship.